- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01252459
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme (GLIAA)
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The higher sensitivity and specificity of amino-acids (L-[methyl-11C]-methionine, MET and O-(2-(1)-Fluoroethyl)-L-tyrosine, FET) positron emission tomography (AA-PET) in the diagnosis of gliomas in comparison to computed tomography (CT) and magnetic resonance imaging (MRI) was demonstrated in many studies and is the rationale for using them in target volume delineation of these tumors. Several clinical trials have demonstrated the significant differences between AA-PET and standard MRI in gross tumor volume (GTV) delineation for treatment planning.
A small prospective study in patients with recurrent high grade gliomas treated with stereotactic fractionated radiotherapy (SFRT) showed a significant improvement in survival when AA-PET or single photon emission tomography (AA-SPECT) were integrated in target volume delineation, in comparison to patients treated using CT/MRI alone (Grosu et al. 2005).
However, there are no randomized studies demonstrating the impact of AA-PET based irradiation treatment on the clinical follow-up in comparison to a traditional MRI/CT based treatment.
The goal of this study is to evaluate the impact of radiotherapy target volume delineation based on AA-PET (new strategy) on the clinical outcome of patients with recurrent glioblastoma (GBM) compared to target volume delineation based on contrast enhanced T1 weighted MRI (T1Gd-MRI) (traditional, established strategy). Concerning therapeutic safety, the topography of recurrence outside the primary target volume as well as the localization of necrosis after the re-irradiation will be determined. All side effects will be assessed by CTCAE version 4.0 and the safety analyses will present the worst grade of acute and late side effect by treatment arm for the whole study period (treatment and follow up). Patients will be asked to complete a quality of life (QoL) questionnaire (as assessed by the E-ORTC QLQ-C15 PAL) in regular time intervals.
This will be the first phase II randomized study evaluating the impact of molecular imaging on outcome after radiotherapy in brain tumor patients.
Another goal of the technical part of this study is the development of a standardized physical-technical methodology for the integration of AA-PET and other imaging biomarkers in tumor volume delineation in radiation therapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Anca-Ligia Grosu, Prof. Dr. med.
- Phone Number: 9520 0049-761-270
- Email: gliaa@uniklinik-freiburg.de
Study Contact Backup
- Name: Ursula Nestle, PD Dr. med.
- Phone Number: 9520 0049-761-270
- Email: gliaa@uniklinik-freiburg.de
Study Locations
-
-
Baden-Wuerttemberg
-
Freiburg i. Br., Baden-Wuerttemberg, Germany, 79106
- Department of Radiotherapy, University Hospital Freiburg
-
Sub-Investigator:
- Nicole Wiedenmann, Dr. med.
-
Sub-Investigator:
- Marianne Schmucker, Dr. med.
-
Sub-Investigator:
- Tanja Schimek-Jasch
-
Principal Investigator:
- Anca-Ligia Grosu, Prof. Dr. med.
-
Principal Investigator:
- Wolfgang Weber, Prof. Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Local recurrence of GBM (WHO grade IV) and either not eligible for tumor resection or with macroscopic residual tumor after resection of recurrent GBM
- Recurrent tumor visible on AA-PET and MRI-T1-Gd with the diameter measuring 1 cm to 6 cm by either technique
- Target volume definition possible according to both study arms
- Previous radiation therapy of the primary with a maximal total dose 60 Gy
- At least 9 months since the end of pre-irradiation and randomisation
- At most 2 prior chemotherapy regimes
- Start of radiation therapy possible within 2 weeks from AA-PET
- Karnofsky Performance Score (KPS) ≥ 70%
- Age ≥ 18 years
- Written informed consent (IC) obtained
Exclusion Criteria:
- - No histological confirmation of Glioma at initial diagnosis)
- Recent (≤ 4 weeks before IC) histological result showing no tumor recurrence
- No recurrent tumor detectable on last AA-PET or MRI-T1-Gd
- Technical impossibility to use existing AA-PET for RT-planning
- No prior radiation treatment to the primary tumor
- less than 9 months between the end of first radiation treatment and randomisation
- more than 2 previous chemotherapy regimes or previous treatment with Avastin or other molecular targeted therapies
- less than 2 weeks between application of chemotherapy and randomisation
- additional chemotherapy or molecular targeted therapy or further surgery planned before diagnosis of further tumor progression after study intervention
- pregnancy, nursing or patient not willing to prevent pregnancy during treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm A: AA-PET based target volume delineation
Experimental intervention (Arm A): High-precision re-irradiation.
Target volume delineation based on AA-PET.
|
Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week.
Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week.
Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
|
ACTIVE_COMPARATOR: Arm B: T1Gd-MRI based target volume delineation
Control intervention (Arm B): High-precision re-irradiation.
Target volume delineation based on T1Gd-MRI.
|
Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week.
Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week.
Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival (PFS)
Time Frame: 6 months after randomization
|
6 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 1 year after randomisation
|
Kaplan-Meier: Performed on the per protocol population - all patients who are eligible and have started their allocated treatment
|
1 year after randomisation
|
Volumetrical assessment of GTV and PTV
Time Frame: Interim analysis
|
Volumetrical assessment of delineated gross tumor volume (GTV) and planning target volume (PTV) based on AA-PET vs. delineated GTV/PTV based on T1-Gd-MRI.
|
Interim analysis
|
Topography of recurrence
Time Frame: Follow up (end of radiotherapy, 6 and 12 weeks after radiotherapy, then every 3 months)
|
local relationship between recurrence and AA-PEt and MRI-derived TV
|
Follow up (end of radiotherapy, 6 and 12 weeks after radiotherapy, then every 3 months)
|
Localisation of necrosis after re-irradiation
Time Frame: Follow up (end of radiotherapy, 6 and 12 weeks after radiotherapy, then every 3 months)
|
Follow up (end of radiotherapy, 6 and 12 weeks after radiotherapy, then every 3 months)
|
|
Rate of long-term survivors
Time Frame: Follow up
|
Rate of long-term survivors = Survivors > 1 year after randomisation
|
Follow up
|
Quality of Life (QoL)
Time Frame: During Radiotherapy and Follow Up
|
QoL assessed by the EORTC QlQ-C 15 PAL questionnaire
|
During Radiotherapy and Follow Up
|
Rate of side effects
Time Frame: During Radiotherapy and Follow Up
|
Assessed according to CTCAE
|
During Radiotherapy and Follow Up
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Anca-Ligia Grosu, Prof. Dr. med., Department of Radiotherapy, University Hospital Freiburg
- Study Chair: Wolfgang Weber, Prof. Dr. med., Department of Nuclear Medicine, University Hospital Freiburg
- Study Chair: Ursula Nestle, PD Dr. med., Department of Radiotherapy, University Hospital Freiburg
Publications and helpful links
General Publications
- Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010 Sep;96(3):325-7. doi: 10.1016/j.radonc.2010.08.001. Epub 2010 Aug 20.
- Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9. doi: 10.1016/j.ijrobp.2005.01.056.
- Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, Gumprecht H, Jaeger R, Schwaiger M, Molls M. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74. doi: 10.1016/j.ijrobp.2005.01.045.
- Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005 Aug;181(8):483-99. doi: 10.1007/s00066-005-1422-7.
- Grosu AL, Lachner R, Wiedenmann N, Stark S, Thamm R, Kneschaurek P, Schwaiger M, Molls M, Weber WA. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1450-63. doi: 10.1016/s0360-3016(03)00279-7.
- Grosu AL, Feldmann H, Dick S, Dzewas B, Nieder C, Gumprecht H, Frank A, Schwaiger M, Molls M, Weber WA. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54. doi: 10.1016/s0360-3016(02)02984-x.
- Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000 May;27(5):542-9. doi: 10.1007/s002590050541.
- Grosu AL, Weber W, Feldmann HJ, Wuttke B, Bartenstein P, Gross MW, Lumenta C, Schwaiger M, Molls M. First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):517-26. doi: 10.1016/s0360-3016(00)00423-5.
- Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Gotz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu AL. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer. 2016 Oct 5;16(1):769. doi: 10.1186/s12885-016-2806-z.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG NUK/RT 2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioma (Glioblastoma Multiforme)
-
Sun Yat-sen UniversityUnknown
-
Novartis PharmaceuticalsCompletedRecurrent Glioblastoma MultiformeUnited States, Belgium, Australia, Spain, France, Canada
-
CASI Pharmaceuticals, Inc.CompletedRecurrent Glioblastoma MultiformeUnited States
-
WPD Pharmaceuticals Sp. z o.o.National Center for Research and Development, Poland; Worldwide Clinical TrialsRecruitingRecurrent Glioblastoma MultiformePoland
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Accendatech USA Inc.Avance Clinical Pty Ltd.; C3 Research AssociatesRecruitingRecurrent Glioblastoma Multiforme(GBM)United States
-
NovartisTerminatedRecurrent Glioblastoma Multiforme (GBM)United States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Active, not recruitingRecurrent Glioblastoma Multiforme | Progressive Glioblastoma Multiforme | Anaplastic Astrocytoma or GliosarcomaUnited States
-
University of Alabama at BirminghamNot yet recruitingRecurrent Malignant Glioma | Glioblastoma Multiforme of Brain | Anaplastic Astrocytoma of Brain | Gliosarcoma of BrainUnited States
Clinical Trials on Radiation Therapy
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
Medical College of WisconsinRecruitingHead and Neck CancerUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
University of California, San FranciscoVarian Medical SystemsRecruitingStage IV Anal Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Postneoadjuvant Therapy Stage... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
Medical College of WisconsinActive, not recruitingHigh-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB) (SIB)Prostate CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal HPV-Positive Squamous Cell CarcinomaUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina